210 related articles for article (PubMed ID: 19470738)
21. Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
Kaneko N; Mitsuoka K; Amino N; Yamanaka K; Kita A; Mori M; Miyoshi S; Kuromitsu S
Clin Cancer Res; 2014 Apr; 20(7):1814-22. PubMed ID: 24486595
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, distribution and excretion of YM155 monobromide, a novel small-molecule survivin suppressant, in male and pregnant or lactating female rats.
Minematsu T; Sonoda T; Hashimoto T; Iwai M; Oppeneer T; Felder L; Shirai N; Miyashita A; Usui T
Biopharm Drug Dispos; 2012 Apr; 33(3):160-9. PubMed ID: 22374735
[TBL] [Abstract][Full Text] [Related]
24. Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant.
Kawano H; Shakushiro K; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
Eur J Pharm Biopharm; 2014 Sep; 88(1):283-9. PubMed ID: 24993306
[TBL] [Abstract][Full Text] [Related]
25. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
Iwasa T; Okamoto I; Takezawa K; Yamanaka K; Nakahara T; Kita A; Koutoku H; Sasamata M; Hatashita E; Yamada Y; Kuwata K; Fukuoka M; Nakagawa K
Br J Cancer; 2010 Jun; 103(1):36-42. PubMed ID: 20517311
[TBL] [Abstract][Full Text] [Related]
26. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.
Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Kinoyama I; Matsuhisa A; Kudou M; Sasamata M
Cancer Sci; 2011 Mar; 102(3):614-21. PubMed ID: 21205082
[TBL] [Abstract][Full Text] [Related]
27. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells.
Liang H; Zhang L; Xu R; Ju XL
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2909-15. PubMed ID: 24254560
[TBL] [Abstract][Full Text] [Related]
28. Survivin selective inhibitor YM155 promotes cisplatin‑induced apoptosis in embryonal rhabdomyosarcoma.
Ueno T; Uehara S; Nakahata K; Okuyama H
Int J Oncol; 2016 May; 48(5):1847-54. PubMed ID: 26983495
[TBL] [Abstract][Full Text] [Related]
29. Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant.
Iwai M; Minematsu T; Narikawa S; Usui T; Kamimura H
Drug Metab Dispos; 2009 Sep; 37(9):1856-63. PubMed ID: 19520775
[TBL] [Abstract][Full Text] [Related]
30. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
Minematsu T; Iwai M; Umehara K; Usui T; Kamimura H
Drug Metab Dispos; 2010 Jan; 38(1):1-4. PubMed ID: 19833842
[TBL] [Abstract][Full Text] [Related]
31. Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells.
Zhang W; Liu Y; Li YF; Yue Y; Yang X; Peng L
Cell Physiol Biochem; 2016; 38(6):2426-37. PubMed ID: 27287458
[TBL] [Abstract][Full Text] [Related]
32. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
33. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells.
Tao YF; Lu J; Du XJ; Sun LC; Zhao X; Peng L; Cao L; Xiao PF; Pang L; Wu D; Wang N; Feng X; Li YH; Ni J; Wang J; Pan J
BMC Cancer; 2012 Dec; 12():619. PubMed ID: 23267699
[TBL] [Abstract][Full Text] [Related]
34. Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells.
Wang Q; Chen Z; Diao X; Huang S
Cancer Lett; 2011 Mar; 302(1):29-36. PubMed ID: 21220185
[TBL] [Abstract][Full Text] [Related]
35. Survivin and YM155: how faithful is the liaison?
Rauch A; Hennig D; Schäfer C; Wirth M; Marx C; Heinzel T; Schneider G; Krämer OH
Biochim Biophys Acta; 2014 Apr; 1845(2):202-20. PubMed ID: 24440709
[TBL] [Abstract][Full Text] [Related]
36. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
Forouzesh B; Hidalgo M; Chu Q; Mita A; Mita M; Schwartz G; Jimeno J; Gómez J; Alfaro V; Lebedinsky C; Zintl P; Rowinsky EK
Clin Cancer Res; 2009 May; 15(10):3591-9. PubMed ID: 19417019
[TBL] [Abstract][Full Text] [Related]
37. Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.
Kaneko N; Yamanaka K; Kita A; Tabata K; Akabane T; Mori M
Biol Pharm Bull; 2013; 36(12):1921-7. PubMed ID: 24432379
[TBL] [Abstract][Full Text] [Related]
38. Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model.
Murakami Y; Matsuya T; Kita A; Yamanaka K; Noda A; Mitsuoka K; Nakahara T; Miyoshi S; Nishimura S
Nucl Med Biol; 2013 Feb; 40(2):221-6. PubMed ID: 23141550
[TBL] [Abstract][Full Text] [Related]
39. Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [
Mitsuoka K; Kita A; Murakami Y; Shirasuna K; Noda A; Yamanaka K; Kaneko N; Miyoshi S
Nucl Med Biol; 2018; 64-65():41-46. PubMed ID: 30041149
[TBL] [Abstract][Full Text] [Related]
40. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.
Kita A; Nakahara T; Yamanaka K; Nakano K; Nakata M; Mori M; Kaneko N; Koutoku H; Izumisawa N; Sasamata M
Leuk Res; 2011 Jun; 35(6):787-92. PubMed ID: 21237508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]